Upcoming Live Webinar and Q&A Session with Dr Brian D. Adams of Harvard Medical School and sponsorde by Abcam:
“MicroRNAs as biomarkers and therapeutic targets in triple negative breast cancer”
January 21, 2016 | 11:00am EST/ 8:00am PST
Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity because of its aggressive behavior, increased incidence in younger women, and lack of effective targeted therapies. miRNAs could serve as superior therapeutic agents for this breast cancer type.
This webinar will review:
- miRNAs and noncoding RNA biology
- Dysregulation of miRNAs associates with disease etiology
- miRNAs as biomarkers
- Techniques used to profile and study miRNA biology
- miRNAs as therapeutic agents and/or targets
Can’t attend the live webinar? Don’t worry! Simply register today and receive the on-demand recording in your inbox within 24 hours of the live event.
About the Speaker:
Brian D. Adams is currently an Instructor at Harvard Medical School in the lab of Dr Frank Slack with over 9 years of experience in the fields of microRNA and cancer research. Brian completed his graduate studies at the University of Connecticut, where he was the first to identify that miRNAs are a crucial regulator of hormone-responsiveness in breast cancer patients. He further completed his postdoctoral studies at Yale, where he investigated how miRNAs can serve as chemo-sensitizers in the context of normal hematopoietic recovery and acute myeloid leukemia.
Incoming search terms for this article:
OncomiRs is a new international, peer-reviewed, open-access journal that welcomes research relevant to the interdisciplinary nature of microRNAs and cancer biology. The journal publishes original research articles and reviews covering all the basics aspects of the microRNAs in tumor formation and development as well as their role in the treatment sensitivity and resistance. OncomiRs focuses on the basic principles of microRNAs in the regulation of cellular processes such as apoptosis, cell cycle control, metastatic dissemination, cellular senescence and immortalization. A particular attention is given to microRNA-controlled regulation of cellular oncogenes and tumor suppressor genes.
Submitting to OncomiRs gives a unique chance to highlight findings in the only specialized microRNA and cancer research journal. Moreover, due to its open access model of publication, manuscripts accepted for publication are immediately published on-line. A submission to OncomiRs also provides an opportunity to present work to our prominent Advisory Board as well as obtain advices from them.
The first article featured in OncomiRs comes from the A. Harel-Bellan’s lab from Paris Sud University in France. The paper “Mir-205 modulates acinar size and morphology of transformed breast epithelial cells” studied the function of miR-205 in cellular formation of breast cancer. Indeed normal breast epithelial cells form highly organized multi-cellular structures, the breast lobules, terminating in [click to continue…]
Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem as a unifying molecular mechanism of tamoxifen resistance has remained elusive.
Researchers at UC, Denver and Tulane University examined the influence of microRNAs (miRNAs) on tamoxifen resistance in both breast tumor samples and cell models of tamoxifen resistance. They compared miRNA expression profiles of tamoxifen sensitive and tamoxifen resistant MCF-7 cells and observed significant and dramatic downregulation of miR-342 in the tamoxifen resistant cells. Expression of miR-342 was also reduced in a panel of tamoxifen refractory human breast tumors, underscoring the potential clinical importance of miR-342 downregulation.
Restoring miR-342 expression in the resistant MCF-7 cell lines sensitized these cells to tamoxifen-induced apoptosis with a dramatic reduction in cell growth. Global gene expression analysis of the restored cells by microarray identified direct and indirect targets of miR-342 not limited to those predicted in silica.
These findings suggest that miR-342 regulates tamoxifen response in breast tumor cell lines and the clinical data indicates a trend towards reduced miR-342 expression and tamoxifen resistance. In addition, the results suggest that miR-342 regulates expression of genes involved in tamoxifen mediated tumor cell apoptosis and cell cycle progression. Restoring miR-342 expression may represent a novel therapeutic approach to sensitizing and suppressing the growth of tamoxifen refractory breast tumors.
Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. (2010) Downregulation of miR-342 is Associated with Tamoxifen Resistant Breast Tumors. Mol Cancer [Epub ahead of print]. [article]